Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey

Torben Bjerregaard Larsen*, Tatjana Potpara, Nikolaos Dagres, Laurent Pison, Heidi Estner, Carina Blomstrom-Lundqvist

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)


The aim of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke and bleeding risk evaluation in atrial fibrillation, particularly regarding the use of risk evaluation schemes, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of these risk assessment schemes. There were some obvious practice differences. However, reassuring information on current practice in Europe was evident, but more focus on renal function is warranted, especially facing the fact that novel oral anticoagulants are used for antithrombotic therapy.
Original languageEnglish
Pages (from-to)698-702
JournalEP Europace
Issue number5
Publication statusPublished - May 2014


  • Atrial fibrillation
  • Anticoagulation
  • Stroke
  • Bleeding
  • Risk stratification
  • CHADS(2)
  • CHA(2)DS(2)-VASc
  • New oral anticoagulants
  • Warfarin
  • EHRA survey
  • EP wire
  • Guidelines

Cite this